These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 33229136)

  • 1. Current status in the discovery of dual BET/HDAC inhibitors.
    Ren Q; Gao W
    Bioorg Med Chem Lett; 2021 Jan; 31():127671. PubMed ID: 33229136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current status in the discovery of dual BET/HDAC inhibitors.
    Ren Q; Gao W
    Bioorg Med Chem Lett; 2021 Apr; 38():127829. PubMed ID: 33685790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting epigenetic reader and eraser: Rational design, synthesis and in vitro evaluation of dimethylisoxazoles derivatives as BRD4/HDAC dual inhibitors.
    Zhang Z; Hou S; Chen H; Ran T; Jiang F; Bian Y; Zhang D; Zhi Y; Wang L; Zhang L; Li H; Zhang Y; Tang W; Lu T; Chen Y
    Bioorg Med Chem Lett; 2016 Jun; 26(12):2931-2935. PubMed ID: 27142751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy.
    Liu T; Wan Y; Xiao Y; Xia C; Duan G
    J Med Chem; 2020 Sep; 63(17):8977-9002. PubMed ID: 32320239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overview of class I HDAC modulators: Inhibitors and degraders.
    Huang Z; Zeng L; Cheng B; Li D
    Eur J Med Chem; 2024 Oct; 276():116696. PubMed ID: 39094429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-based design, synthesis and in vitro antiproliferative effects studies of novel dual BRD4/HDAC inhibitors.
    Shao M; He L; Zheng L; Huang L; Zhou Y; Wang T; Chen Y; Shen M; Wang F; Yang Z; Chen L
    Bioorg Med Chem Lett; 2017 Sep; 27(17):4051-4055. PubMed ID: 28765013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The discovery of colchicine-SAHA hybrids as a new class of antitumor agents.
    Zhang X; Zhang J; Tong L; Luo Y; Su M; Zang Y; Li J; Lu W; Chen Y
    Bioorg Med Chem; 2013 Jun; 21(11):3240-4. PubMed ID: 23602523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of selective HDAC/BRD4 dual inhibitors as epigenetic probes.
    Chen J; Li Y; Zhang J; Zhang M; Wei A; Liu H; Xie Z; Ren W; Duan W; Zhang Z; Shen A; Hu Y
    Eur J Med Chem; 2021 Jan; 209():112868. PubMed ID: 33077265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
    Sangwan R; Rajan R; Mandal PK
    Eur J Med Chem; 2018 Oct; 158():620-706. PubMed ID: 30245394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors.
    Chen J; Li D; Li W; Yin J; Zhang Y; Yuan Z; Gao C; Liu F; Jiang Y
    Bioorg Med Chem; 2018 Aug; 26(14):3958-3966. PubMed ID: 29954683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Synthesis and activity of some new histone deacetylases inhibitors].
    Cheng YH; Guo YS; Han HZ; Wang N; Zhang GH; Guo ZR; Wu S
    Yao Xue Xue Bao; 2010 Jun; 45(6):735-41. PubMed ID: 20939182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitors of histone deacetylase as antitumor agents: A critical review.
    Manal M; Chandrasekar MJ; Gomathi Priya J; Nanjan MJ
    Bioorg Chem; 2016 Aug; 67():18-42. PubMed ID: 27239721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of the first histone deacetylase 6/8 dual inhibitors.
    Olson DE; Wagner FF; Kaya T; Gale JP; Aidoud N; Davoine EL; Lazzaro F; Weïwer M; Zhang YL; Holson EB
    J Med Chem; 2013 Jun; 56(11):4816-20. PubMed ID: 23672185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural basis for the design and synthesis of selective HDAC inhibitors.
    Di Micco S; Chini MG; Terracciano S; Bruno I; Riccio R; Bifulco G
    Bioorg Med Chem; 2013 Jul; 21(13):3795-807. PubMed ID: 23693069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multitarget Inhibition of Histone Deacetylase (HDAC) and Phosphatidylinositol-3-kinase (PI3K): Current and Future Prospects.
    Rodrigues DA; Pinheiro PSM; Fraga CAM
    ChemMedChem; 2021 Feb; 16(3):448-457. PubMed ID: 33049098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, Synthesis and Biological Evaluation of Novel Benzoylimidazole Derivatives as Raf and Histone Deacetylases Dual Inhibitors.
    Chen X; Gong G; Chen X; Song R; Duan M; Qiao R; Jiao Y; Qi J; Chen Y; Zhu Y
    Chem Pharm Bull (Tokyo); 2019; 67(10):1116-1122. PubMed ID: 31582631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From natural products to HDAC inhibitors: An overview of drug discovery and design strategy.
    Qiu X; Zhu L; Wang H; Tan Y; Yang Z; Yang L; Wan L
    Bioorg Med Chem; 2021 Dec; 52():116510. PubMed ID: 34826681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-tumor activity evaluation of novel tubulin and HDAC dual-targeting inhibitors.
    Wang B; Chen X; Gao J; Su L; Zhang L; Xu H; Luan Y
    Bioorg Med Chem Lett; 2019 Sep; 29(18):2638-2645. PubMed ID: 31400938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors.
    Zhao C; Zang J; Ding Q; Inks ES; Xu W; Chou CJ; Zhang Y
    Eur J Med Chem; 2018 Apr; 150():282-291. PubMed ID: 29533873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and synthesis of novel isoxazole-based HDAC inhibitors.
    Conti P; Tamborini L; Pinto A; Sola L; Ettari R; Mercurio C; De Micheli C
    Eur J Med Chem; 2010 Sep; 45(9):4331-8. PubMed ID: 20637529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.